Products for Research Use Only
RegisterLogin

Lusutrombopag-d13

CAT: 0804-HY-19883SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19883SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
Product Name Alternative
S-888711-d13
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Thrombopoietin Receptor
Type
Isotope-Labeled Compounds
Related Pathways
Immunology/Inflammation; Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Purity
98.64
Solubility
DMSO : 50 mg/mL (ultrasonic; warming)
Smiles
O=C(O)/C(C)=C/C1=C(Cl)C=C(C(NC2=NC(C3=CC=CC([C@@H](OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])C)=C3OC)=CS2)=O)C=C1Cl
Molecular Formula
C29H19D13Cl2N2O5S
Molecular Weight
604.63
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76 (1) :155-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-19883-01Lusutrombopag
HY-19883R-01Lusutrombopag (Standard)
HY-W514721-01D13
HY-N0097S5-01Guanosine-d13
HY-W708756-01Butachlor-d13
HY-124819-01D13-9001
HY-D0858S-01MES-d13
HY-W739267Fenazaquin-d13
HY-W040193S6DSPC-d13
HY-B0228S12-01Adenosine-d13

Alternative Products

CatalogName
CS-T-103719Lusutrombopag-d13
453983-01Lusutrombopag

Popular Products